Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.36
+$0.41 · +10.38%
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Previous close
$4.36
+$0.41 · +10.38%
After-hours
$4.39
+$0.03 · +0.69%
Oct 9, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Day range
Current $4.36
52-week range
Current $4.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
50
Fair Value
Sentiment
62
Bullish
Risk
63
High Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Day range
Current $4.36
52-week range
Current $4.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 74.68M USD | 58.84M USD | 43.88M USD | 39.68M USD | 10M USD |
| Cost of goods sold | 120.95M USD | 45.24M USD | 42.59M USD | 48.28M USD | — |
| Gross profit | −46.27M USD | 13.6M USD | 1.29M USD | −8.59M USD | 10M USD |
| Research and development | 425.27M USD | 314.42M USD | 241.23M USD | 155.7M USD | 135.27M USD |
| Selling, general, and administrative | 176.59M USD | 178.18M USD | 110.82M USD | 81.6M USD | 57.68M USD |
| Operating expenses | 601.86M USD | 492.61M USD | 351.35M USD | 237.13M USD | 192.78M USD |
| Interest income | 22.79M USD | 15.76M USD | 19.12M USD | 6.25M USD | 73K USD |
| Interest expense | 1.81M USD | 1.57M USD | 97K USD | 55K USD | 2.95M USD |
| Depreciation and amortization | 83.7M USD | 36.49M USD | 24.4M USD | 11.76M USD | 8.41M USD |
| Operating income | −648.13M USD | −479M USD | −350.06M USD | −245.73M USD | −182.78M USD |
| Net income | −644.76M USD | −463.66M USD | −328.07M USD | −239.48M USD | −186.48M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.30
21.56% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK87.23M1.27%5.56B USD0.75%$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI68.07M0.67%9.87B USD0.35%$153.77+3.00%
ARK Genomic Revolution ETFARKG58.17M2.84%1.56B USD0.75%$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI54.05M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM53.49M0.07%78.27B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB38.97M0.02%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK22.33M0.05%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF20.71M0.02%95.4B USD0.05%$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
